Skip to main content
CRMD
NASDAQ Life Sciences

CorMedix Reports Strong Q4 & Full-Year 2025 Results, Reiterates 2026 Guidance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$6.75
Mkt Cap
$560.978M
52W Low
$5.6
52W High
$17.43
52W Position info
21% above low
Off High info
61% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

CRMD sits 21% above its 52-week low of $5.6.

Summary

CorMedix Inc. announced robust financial results for Q4 and full-year 2025, reporting significant revenue growth and a substantial shift to profitability, while reaffirming its positive 2026 guidance.


Key Events · Earnings and Guidance · CRMD

  • Strong Q4 2025 Financial Performance

    CorMedix reported net revenue of $128.6 million and net income of $14.0 million for the fourth quarter of 2025, significantly up from the comparable period in 2024.

  • Significant Full-Year Profitability Turnaround

    For the full year 2025, the company achieved total revenue of $311.7 million (pro forma $401.3 million) and a net income of $163.0 million, a substantial improvement from a net loss of $17.9 million in 2024.

  • 2026 Guidance Reaffirmed

    CorMedix reiterated its previously established guidance for fiscal year 2026, projecting net revenue between $300 million and $320 million and adjusted EBITDA between $100 million and $125 million.

  • Healthy Cash Position

    The company ended December 31, 2025, with $148.5 million in cash and short-term investments, excluding restricted cash.


Analysis · CRMD · Life Sciences

CorMedix Inc. announced robust financial results for the fourth quarter and full-year 2025, marking a significant turnaround to profitability driven by strong DefenCath sales and the Melinta acquisition. The substantial net income for the full year, compared to a loss in the prior year, signals successful integration and commercial execution. The reaffirmation of positive 2026 guidance provides a clear outlook for continued growth and profitability, reinforcing investor confidence. Additionally, the company highlighted upcoming clinical data for REZZAYO in Q2 2026, which could serve as a significant near-term catalyst.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 45% of the 1400 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CRMD was trading at $6.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $561M. The 52-week trading range was $5.60 to $17.43. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CRMD - Latest Insights

CRMD
Nov 02, 2026, 7:39 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.50
Real-time Price: $5.35 info
Change: -$0.150 (-3%) info
Market Cap: $414.664M info
CRMD
Nov 02, 2026, 7:32 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $5.62
Real-time Price: $5.35 info
Change: -$0.2655 (-5%) info
Market Cap: $414.664M info
CRMD
Oct 19, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.45
Real-time Price: $5.35 info
Change: -$2.10 (-28%) info
Market Cap: $414.664M info
CRMD
Aug 13, 2026, 8:07 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $7.65
Real-time Price: $5.35 info
Change: -$2.30 (-30%) info
Market Cap: $414.664M info
CRMD
Aug 13, 2026, 7:44 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $7.65
Real-time Price: $5.35 info
Change: -$2.30 (-30%) info
Market Cap: $414.664M info